cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2021-2892cardiovascular-2892Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEW ARTICLESМелатонин и сердечно-сосудистая патология: от механизмов действия к возможностям клинического применения (обзор литературы)Melatonin and cardiovascular disease: from mechanisms of action to potential clinical use (literature review)https://orcid.org/0000-0002-4453-8430ДрапкинаО. М.DrapkinaO. M.

Доктор медицинских наук, профессор, член-корр. РАН, директор.

Москва

PhD, ScD, prof., director.

Moscow

drapkina@bk.ruhttps://orcid.org/0000-0003-2062-1536КонцеваяА. В.KontsevayaA. V.

Доктор медицинских наук, зам. директора по научной и аналитической работе.

Москва

PhD, ScD, Deputy director on science and analytic.

Moscow

Akontsevaya@gnicpm.ruhttps://orcid.org/0000-0002-1171-2746БудневскийА. В.BudnevskyA. V.

Доктор медицинских наук, профессор, заведующий кафедрой факультетской терапии 

PhD, ScD, prof., head of the Department of Faculty Therapy

budnev@list.ruhttps://orcid.org/0000-0002-8545-6255ОвсянниковЕ. С.OvsyannikovE. S.

Доктор медицинских наук, доцент кафедры факультетской терапии.

Тел.: +7 (473) 263-81-30

PhD, ScD, associate professor at the Department of Faculty Therapy

ovses@yandex.ruhttps://orcid.org/0000-0003-2132-8374ДробышеваЕ. С.DrobyshevaE. S.

Кандидат медицинских наук, доцент кафедры факультетской терапии

PhD, associate professor at the Department of Faculty Therapy

e.drobysheva76@mail.ruhttps://orcid.org/0000-0001-6792-6359БолотскихВ. И.BolotskihV. I.

Доктор медицинских наук, профессор, заведующий кафедрой патологической физиологии

PhD, ScD, head of the Department of Pathophysiology

vibolotskih@vrngmu.ruhttps://orcid.org/0000-0002-4926-167XМакееваА. В.MakeevaA. V.

Кандидат биологических наук, доцент кафедры патологической физиологии 

PhD, associate professor at the Department of Pathophysiology

a.makeeva@vsmaburdenko.ruhttps://orcid.org/0000-0002-1273-8374ЛущикМ. В.LushchikM. V.

Кандидат биологических наук, доцент кафедры патологической физиологии

PhD, associate professor at the Department of Pathophysiology

m.lushhik@vrngmu.ruФГБУ Национальный медицинский исследовательский центр терапии и профилактической медицины Минздрава РоссииNational Medical Research Center for Therapy and Preventive MedicineФГБОУ ВО Воронежский государственный медицинский университет им. Н.Н. Бурденко Минздрава РоссииN.N. Burdenko Voronezh State Medical University20210901202220828922892Copyright © Драпкина О.М., Концевая А.В., Будневский А.В., Овсянников Е.С., Дробышева Е.С., Болотских В.И., Макеева А.В., Лущик М.В., 20222022Драпкина О.М., Концевая А.В., Будневский А.В., Овсянников Е.С., Дробышева Е.С., Болотских В.И., Макеева А.В., Лущик М.В.Drapkina O.M., Kontsevaya A.V., Budnevsky A.V., Ovsyannikov E.S., Drobysheva E.S., Bolotskih V.I., Makeeva A.V., Lushchik M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/2892

Кардиоваскулярная патология остается наиболее актуальной проблемой здравоохранения. Большинство сердечно-сосудистых заболеваний связаны с атеросклеротическим процессом, развитие которого ассоциируется с воспалением и дисфункцией эндотелия. Мелатонин представляет собой нейрогормон, который синтезируется преимущественно в эпифизе и играет центральную роль в регуляции сна и некоторых других циклических процессов в организме. Долгое время мелатонин воспринимался исключительно как вещество, эффективное в лечении нарушений биологических ритмов. Вместе с тем, в последнее время накопилось большое количество работ, которые демонстрируют более широкий диапазон его биологических эффектов, включая противовоспалительный, антиоксидантный, антигипертензивный и, возможно, гиполипидемический. В обзор включены современные данные экспериментальных и клинических исследований, демонстрирующие кардиопротектив-ные эффекты мелатонина при атеросклерозе, ишемии миокарда и сердечной недостаточности.

Cardiovascular disease remains the most relevant public health problem. Most cardiovascular diseases are associated with an atherosclerosis, the development of which is associated with inflammation and endothelial dysfunction. Melatonin is a neurohormone that is synthesized mainly in the pineal gland and plays a central role in the regulation of sleep and some other body cyclic processes. For a long time, melatonin was perceived as a substance that is effective in the treatment of circadian cycle impairments. At the same time, a large number of studies have accumulated recently that demonstrate a wider range of its biological effects, including anti-inflammatory, antioxidant, antihypertensive and, possibly, hypolipidemic. The review includes current data from experimental and clinical studies demonstrating the cardioprotective effects of melatonin in atherosclerosis, myocardial ischemia, and heart failure.

мелатонинантиоксидантатеросклерозсердечная недостаточностьmelatoninantioxidantatherosclerosisheart failureReferencesФомин И. В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016;(8):7-13. doi:10.15829/1560-4071-2016-8-7-13.Fomin IV. Chronic heart failure in Russian Federation: what do we know and what to do. Russian Journal of Cardiology. 2016;(8):7-13. (In Russ.) doi:10.15829/1560-4071-2016-8-7-13.Будневский А. В., Малыш Е. Ю. Клинико-патогенетические взаимосвязи сердечно-сосудистых заболеваний и хронической обструктивной болезни легких. Кардиология. 2017;57(4):89-93. doi:10.18565/cardio.2017.4.89-93.Budnevsky AV, Malysh EY. Clinico-pathogenetic relationship of cardiovascular diseases and chronic оbstructive pulmonary disease. Kardiologiia. 2017;57(4):89-93. (In Russ.) doi:10.18565/cardio.2017.4.89-93.Rajani NB, Giannakopoulos G, Filippidis FT. Job insecurity, financial difficulties and mental health in Europe. Occupational Medicine. 2016;66(8):681-3. doi:10.1093/occmed/kqw111.Rajani NB, Giannakopoulos G, Filippidis FT. Job insecurity, financial difficulties and mental health in Europe. Occupational Medicine. 2016;66(8):681-3. doi:10.1093/occmed/kqw111.Бурчаков Д. И., Успенская Ю. Б. Антиоксидантный, противовоспалительный и седативный эффекты мелатонина: результаты клинических исследований. Журнал неврологии и психиатрии. 2017;4(2):67-73. doi:10.17116/jnevro20171174267-73.Burchakov DI, Uspenskaya YU. Antioxidant, anti-inflammatory and sedative effects of melatonin: results of clinical trials. Zhurnal nevrologii i psikhiatrii. 2017;4(2):67-73. (In Russ.) doi:10.17116/jnevro20171174267-73.Melatonin: prospects for clinical use. Eds. Rapoport SI M.: IMA-PRESS, 2012, р. 176. (In Russ.) Мелатонин: перспективы применения в клинике. Под ред. Рапопорта С. И. М.: ИМА-ПРЕСС, 2012. с. 176. ISBN: 978-5-904356-14-9.Melatonin: prospects for clinical use. Eds. Rapoport SI M.: IMA-PRESS, 2012, р. 176. (In Russ.) ISBN: 978-5-904356-14-9.Singhana K, Apaijai N, Chattipakorn SC, et al. Roles of melatonin and its receptors in cardiac ischemia — reperfusion injury. Cell Mol Life Sci. 2018;75(22):4125-49. doi:10.1007/s00018-018-2905-x.Singhana K, Apaijai N, Chattipakorn SC, et al. Roles of melatonin and its receptors in cardiac ischemia — reperfusion injury. Cell Mol Life Sci. 2018;75(22):4125-49. doi:10.1007/s00018-018-2905-x.dos Santos GB, Rodrigues MJM, Goncalves EM, et al. Melatonin reduces oxidative stress and cardiovascular changes induced by stanozolol in rats exposed to swimming exercise. Eurasian J Med. 2013;45(3):155. doi:10.5152/eajm.2013.33.dos Santos GB, Rodrigues MJM, Goncalves EM, et al. Melatonin reduces oxidative stress and cardiovascular changes induced by stanozolol in rats exposed to swimming exercise. Eurasian J Med. 2013;45(3):155. doi:10.5152/eajm.2013.33.Zhong J, Liu Y. Melatonin and age-related cardiovascular diseases. Aging Medicine. 2018; 1 (2): 197-203. doi: 10.1002/agm2.12036.Zhong J, Liu Y. Melatonin and age-related cardiovascular diseases. Aging Medicine. 2018; 1 (2): 197-203. doi: 10.1002/agm2.12036.Васендин Д. В. Медико-биологические эффекты мелатонина: некоторые итоги и перспективы изучения. Вестник Российской военно-медицинской академии. 2016;55(3):171-8.Vasendin DV. Medical and biological effects of melatonin: some results and perspectives of the study. Vestnik Rossijskoj voenno-medicinskoj akademii. 2016;55(3):171-8. (In Russ.)Venegas C, Garcia JA, Escames G, et al. Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J Pineal Res. 2012;52(2):217-27 doi:10.1111/j.1600-079x.2011.00931.x.Venegas C, Garcia JA, Escames G, et al. Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J Pineal Res. 2012;52(2):217-27 doi:10.1111/j.1600-079x.2011.00931.x.Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br J Pharmacol. 2018;175(16):3190-9. doi:10.1111/bph.14116.Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br J Pharmacol. 2018;175(16):3190-9. doi:10.1111/bph.14116.Семёнова Н. В., Мадаева И. М., Колесникова Л. И. Инсомния и циркадные ритмы мелатонина у женщин в менопаузе. Acta Biomedica Scientifica (East Siberian Biomedical Journal). 2018;3(5):16-21. doi:10.29413/ABS.2018-3.5.2.Semenova NV, Madaeva IM, Kolesnikova LI. Insomnia and circadian rhythms of melatonin in menopausal women. Acta Biomedica Scientifica (East Siberian Biomedical Journal). 2018;3(5):16-21. (In Russ.) doi:10.29413/ABS.2018-3.5.2.Ma Q, Reiter RJ, Chen Y. Role of melatonin in controlling angiogenesis under physiological and pathological conditions. Angiogenesis. 2020;23(2):91-104. doi:10.1007/s10456-019-09689-7.Ma Q, Reiter RJ, Chen Y. Role of melatonin in controlling angiogenesis under physiological and pathological conditions. Angiogenesis. 2020;23(2):91-104. doi:10.1007/s10456-019-09689-7.Dominguez-Rodriguez A. Melatonin in cardiovascular disease. Expert Opin Investig Drugs. 2012;21(11):1593-6. doi:10.1517/13543784.2012.716037Dominguez-Rodriguez A. Melatonin in cardiovascular disease. Expert Opin Investig Drugs. 2012;21(11):1593-6. doi:10.1517/13543784.2012.716037Rahbarghazi A, Siahkouhian M, Rahbarghazi R, et al. Role of melatonin in the angiogenesis potential; highlights on the cardiovascular disease. J Inflam. 2021;18(4):2021. doi:10.1186/s12950-021-00269-5.Rahbarghazi A, Siahkouhian M, Rahbarghazi R, et al. Role of melatonin in the angiogenesis potential; highlights on the cardiovascular disease. J Inflam. 2021;18(4):2021. doi:10.1186/s12950-021-00269-5.Hussein MR, Ahmed OG, Hassan AF, et al. Intake of melatonin is associated with amelioration of physiological changes, both metabolic and morphological pathologies associated with obesity: an animal model. Int J Exp Pathol. 2007;88(1):19-29. doi:10.1111/j.1365-2613.2006.00512.x.Hussein MR, Ahmed OG, Hassan AF, et al. Intake of melatonin is associated with amelioration of physiological changes, both metabolic and morphological pathologies associated with obesity: an animal model. Int J Exp Pathol. 2007;88(1):19-29. doi:10.1111/j.1365-2613.2006.00512.x.She M, Deng X, Guo Z, et al. NEU-P11, a novel melatonin agonist, inhibits weight gain and improves insulin sensitivity in high-fat/ high-sucrose-fed rats. Pharmacol Res. 2009;59(4):248-53. doi:10.1016/j.phrs.2009.01.005.17 She M, Deng X, Guo Z, et al. NEU-P11, a novel melatonin agonist, inhibits weight gain and improves insulin sensitivity in high-fat/ high-sucrose-fed rats. Pharmacol Res. 2009;59(4):248-53. doi:10.1016/j.phrs.2009.01.005.Sehirli AO, Koyun D, Tetik S, et al. Melatonin protects against ischemic heart failure in rats. J Pineal Res. 2013;55(2): 138-48. doi:10.1111/jpi.12054.Sehirli AO, Koyun D, Tetik S, et al. Melatonin protects against ischemic heart failure in rats. J Pineal Res. 2013;55(2): 138-48. doi:10.1111/jpi.12054.Mukherjee D, Roy SG, Bandyopadhyay A, et al. Melatonin protects against isoproterenol-induced myocardial injury in the rat: antioxidative mechanisms. J Pineal Res. 2010;48(3):251-62. doi:10.1111/j.1600-079x.2010.00749.x.Mukherjee D, Roy SG, Bandyopadhyay A, et al. Melatonin protects against isoproterenol-induced myocardial injury in the rat: antioxidative mechanisms. J Pineal Res. 2010;48(3):251-62. doi:10.1111/j.1600-079x.2010.00749.x.Rahim I, Sayed RK., Fernandez-Ortiz M, et al. Melatonin alleviates sepsis-induced heart injury through activating the Nrf2 pathway and inhibiting the NLRP3 inflammasome. Naunyn-Schmiedeberg’s Arch Pharmacol. 2021;394(2):261-77 doi:10.1007/s00210-020-01972-5.Rahim I, Sayed RK., Fernandez-Ortiz M, et al. Melatonin alleviates sepsis-induced heart injury through activating the Nrf2 pathway and inhibiting the NLRP3 inflammasome. Naunyn-Schmiedeberg’s Arch Pharmacol. 2021;394(2):261-77 doi:10.1007/s00210-020-01972-5.Mayo JC, Sainz RM, Tan DX, et al. Anti-iflammatory actions of melatonin and its metabolites, N1-acetyl-5 methoxykynuramine (AMK) in macrophages. J Neuroimmynol. 2005;165(1-2):139-49. doi:10.1016/j.jneuroim.2005.05.002.Mayo JC, Sainz RM, Tan DX, et al. Anti-iflammatory actions of melatonin and its metabolites, N1-acetyl-5 methoxykynuramine (AMK) in macrophages. J Neuroimmynol. 2005;165(1-2):139-49. doi:10.1016/j.jneuroim.2005.05.002.Будневский А. В., Цветикова Л. Н., Овсянников Е. С. и др. Мелатонин: роль в развитии хронической обструктивной болезни легких. Пульмонология. 2016;26(3):372-8. doi: 10.18093/0869-0189-2016-26-3-372-378.Budnevskiy AV, Tsvetikova LN, Ovsyannikov ES, et al. A role of melatonin for occurrence of chronic obstructive pulmonary disease. Pulmonologiya. 2016;26(3):372-8. (In Russ.) doi: 10.18093/0869-0189-2016-26-3-372-378.Цветикова Л. Н., Буднев-ский А. В., Овсянников Е. С. и др. Мелатонин: возможности использования в терапии бронхиальной астмы. Терапевтический архив. 2017;89(3): 112-5. doi: 10.17116/terarkh2017893112-115.Tsvetikova LN, Budnevsky AV, Ovsyannikov ES, et al. Melatonin: Possibilities for use in the treatment of asthma. Terapevticheskii Arkhiv. 2017;89(3):112-5. (In Russ.) doi: 10.17116/terarkh2017893112-115.Арушанян Э. Б., Наумов С. С. Противовоспалительные возможности мелатонина. Клиническая медицина. 2013;92(7):18-21.Arushanyan EB, Naumov SS. Anti-nflammatory potential of melatonin. Klinicheskaya medicina. 2013;92(7):18-21. (In Russ.)Nabavi SM, Nabavi SF, Sureda A, et al. Anti-inflammatory effects of Melatonin: A mechanistic review. Crit Rev Food Sci Nutr. 2018;59(1):4-6. doi:10.1080/10408398.2018.1487927.Nabavi SM, Nabavi SF, Sureda A, et al. Anti-inflammatory effects of Melatonin: A mechanistic review. Crit Rev Food Sci Nutr. 2018;59(1):4-6. doi:10.1080/10408398.2018.1487927.Yang CH, Xu JH, Ren QC, et al. Melatonin promotes secondary hair follicle development of early postnatal cashmere goat and improves cashmere quantity and quality by enhancing antioxidant capacity and suppressing apoptosis. J Pineal Res. 2019;67(1):e12569. doi:10.1111/jpi.12569.Yang CH, Xu JH, Ren QC, et al. Melatonin promotes secondary hair follicle development of early postnatal cashmere goat and improves cashmere quantity and quality by enhancing antioxidant capacity and suppressing apoptosis. J Pineal Res. 2019;67(1):e12569. doi:10.1111/jpi.12569.Chitimus DM, Popescu MR, Voiculescu SE, et al. Melatonin’s impact on antioxidative and anti-inflammatory programming in homeostasis and disease. Biomolecules. 2020; 10(9): 1211. doi:10.3390/biom10091211.27 Chitimus DM, Popescu MR, Voiculescu SE, et al. Melatonin’s impact on antioxidative and anti-inflammatory programming in homeostasis and disease. Biomolecules. 2020; 10(9): 1211. doi:10.3390/biom10091211.Dominguez-Rodriguez A, Abreu-Gonzalez P, de la Torre-Hernandez JM, et al. Usefulness of early treatment with melatonin to reduce infarct size in patients with ST-segment elevation myocardial infarction receiving percutaneous coronary intervention (from the melatonin adjunct in the acute myocardial infarction treated with angioplasty trial). Am J Cardiol. 2017; 120(4): 522-6. doi:10.1016/j.amjcard.2017.05.018.Dominguez-Rodriguez A, Abreu-Gonzalez P, de la Torre-Hernandez JM, et al. Usefulness of early treatment with melatonin to reduce infarct size in patients with ST-segment elevation myocardial infarction receiving percutaneous coronary intervention (from the melatonin adjunct in the acute myocardial infarction treated with angioplasty trial). Am J Cardiol. 2017; 120(4): 522-6. doi:10.1016/j.amjcard.2017.05.018.Prado NJ, Ferder L, Manucha W, et al. Anti-inflammatory effects of melatonin in obesity and hypertension. Curr Hypertens Rep. 2018;20(5):45. doi:10.1007/s11906-018-0842-6.Prado NJ, Ferder L, Manucha W, et al. Anti-inflammatory effects of melatonin in obesity and hypertension. Curr Hypertens Rep. 2018;20(5):45. doi:10.1007/s11906-018-0842-6.Sahna E, Parlakpinar H, Turkoz Y, et al. Protective effects of melatonin on myocardial ischemia/reperfusion induced infarct size and oxidative changes. Physiol Res. 2005;54(5):491-5.Sahna E, Parlakpinar H, Turkoz Y, et al. Protective effects of melatonin on myocardial ischemia/reperfusion induced infarct size and oxidative changes. Physiol Res. 2005;54(5):491-5.Cecon E, Oishi A, Jockers R. Melatonin receptors: molecular pharmacology and signalling in the oantext of system bias. Br J Pharmacol. 2018;175(16):3263-80. doi: 10.1111/bph.13950.Cecon E, Oishi A, Jockers R. Melatonin receptors: molecular pharmacology and signalling in the oantext of system bias. Br J Pharmacol. 2018;175(16):3263-80. doi: 10.1111/bph.13950.Sallinen P, Manttari S, Leskinen H, et al. The effect of myocardial infarction on the synthesis, concentration and receptor expression of endogenous melatonin. J Pineal Res. 2007;42(3):254-60. doi:10.1111/j.1600-079x.2006.00413.x.Sallinen P, Manttari S, Leskinen H, et al. The effect of myocardial infarction on the synthesis, concentration and receptor expression of endogenous melatonin. J Pineal Res. 2007;42(3):254-60. doi:10.1111/j.1600-079x.2006.00413.x.Stroethoff M, Behmenburg F, Spittler K, et al. Activation of melatonin receptors by ramelteon induces cardioprotection by postconditioning in the rat heart. Anesth Analg. 2018;126(6):2112-5. doi:10.1213/ane.0000000000002625.Stroethoff M, Behmenburg F, Spittler K, et al. Activation of melatonin receptors by ramelteon induces cardioprotection by postconditioning in the rat heart. Anesth Analg. 2018;126(6):2112-5. doi:10.1213/ane.0000000000002625.Цибульников С. Ю., Горбунов А. С., Прокудина Е. С. и др. Мелатонин и его роль в регуляции устойчивости сердца к действию ишемии и реперфузии. Патологическая физиология и экспериментальная терапия. 2020;64(1): 142-6. doi: 10.25557/0031-2991.2020.01.142-146.Tsibulnikov SYu, Gorbunov AS, Prokudina ES, et al. Melatonin and its role in regulating heart resistance to ischemia and reperfusion. Pathological Physiology and Experimental Therapy. 2020;64(1):142-6. (In Russ.) doi: 10.25557/0031-2991.2020.01.142-146.Ghaeli P, Vejdani S, Ariamanesh A, et al. Effect of melatonin on cardiac injury after primary percutaneous coronary intervention: a randomized controlled trial. Iran J Pharm Res. 2015;14(3):851-5.Ghaeli P, Vejdani S, Ariamanesh A, et al. Effect of melatonin on cardiac injury after primary percutaneous coronary intervention: a randomized controlled trial. Iran J Pharm Res. 2015;14(3):851-5.Dwaich KH, Al-Amran FG, Al-Sheibani BI, et al. Melatonin effects on myocardial ischemia-reperfusion injury: Impact on the outcome in patients undergoing coronary artery bypass grafting surgery. Int J Cardiol. 2016;221:977-86. doi:10.1016/j.ijcard.2016.07108.Dwaich KH, Al-Amran FG, Al-Sheibani BI, et al. Melatonin effects on myocardial ischemia-reperfusion injury: Impact on the outcome in patients undergoing coronary artery bypass grafting surgery. Int J Cardiol. 2016;221:977-86. doi:10.1016/j.ijcard.2016.07108.Briasoulis A, Tousoulis DS, Androulakis E, et al. Endothelial dysfunction and atherosclerosis: focus on novel therapeutic approaches. Recent Pat Cardiovasc Drug Disc. 2012;7(1):21-32. doi:10.2174/157489012799362386.Briasoulis A, Tousoulis DS, Androulakis E, et al. Endothelial dysfunction and atherosclerosis: focus on novel therapeutic approaches. Recent Pat Cardiovasc Drug Disc. 2012;7(1):21-32. doi:10.2174/157489012799362386.Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science. 2013;339(6116):166-72. doi:10.1126/science.1230720.Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science. 2013;339(6116):166-72. doi:10.1126/science.1230720.Silvestre-Roig C, de Winther MP, Weber C, et al. Atherosclerotic plaque destabilization. Circ Res. 2014; 114(1 ):214-26. doi:10.1161/circresaha.114.302355.Silvestre-Roig C, de Winther MP, Weber C, et al. Atherosclerotic plaque destabilization. Circ Res. 2014; 114(1 ):214-26. doi:10.1161/circresaha.114.302355.Roifman I, Beck PL, Anderson TJ, et al. Chronic inflammatory diseases and cardiovascular risk: a systematic review. Can J Cardiol. 2011;27(2):174-82. doi:10.1016/j.cjca.2010.12.040.Roifman I, Beck PL, Anderson TJ, et al. Chronic inflammatory diseases and cardiovascular risk: a systematic review. Can J Cardiol. 2011;27(2):174-82. doi:10.1016/j.cjca.2010.12.040.Frohlich J, Al-Sarraf A. Cardiovascular risk and atherosclerosis prevention. Cardiovasc Pathol. 2013;22(1):16-8. doi:10.1016/j.carpath.2012.03.001.Frohlich J, Al-Sarraf A. Cardiovascular risk and atherosclerosis prevention. Cardiovasc Pathol. 2013;22(1):16-8. doi:10.1016/j.carpath.2012.03.001.Li HY, Leu YL, Wu YC, et al. Melatonin inhibits in vitro smooth muscle cell inflammation and proliferation and atherosclerosis in apolipoprotein E-deficient mice. J Agric Food Chem. 2019;67(7):1889-901. doi:10.1021/acs.jafc.8b06217.Li HY, Leu YL, Wu YC, et al. Melatonin inhibits in vitro smooth muscle cell inflammation and proliferation and atherosclerosis in apolipoprotein E-deficient mice. J Agric Food Chem. 2019;67(7):1889-901. doi:10.1021/acs.jafc.8b06217.Ding S, Lin N, Sheng X, et al. Melatonin stabilizes rupture-prone vulnerable plaques via regulating macrophage polarization in a nuclear circadian receptor RORalpha-dependent manner. J Pineal Res. 2019;67(2):e12581. doi:10.1111/jpi.12581.Ding S, Lin N, Sheng X, et al. Melatonin stabilizes rupture-prone vulnerable plaques via regulating macrophage polarization in a nuclear circadian receptor RORalpha-dependent manner. J Pineal Res. 2019;67(2):e12581. doi:10.1111/jpi.12581.Sasso GL, Schlage WK, Boue S, et al. The Apoe-/- mouse model: a suitable model to study cardiovascular and respiratory diseases in the context of cigarette smoke exposure and harm reduction. J Transl Med. 2016;14(1):146. doi:10.1186/s12967-016-0901-1.Sasso GL, Schlage WK, Boue S, et al. The Apoe-/- mouse model: a suitable model to study cardiovascular and respiratory diseases in the context of cigarette smoke exposure and harm reduction. J Transl Med. 2016;14(1):146. doi:10.1186/s12967-016-0901-1.Cheng X, Wan Y, Xu Y, et al. Melatonin alleviates myosin light chain kinase expression and activity via the mitogen-activated protein kinase pathway during atherosclerosis in rabbits. Mol Med Rep. 2015;11(1):99-104. doi:10.3892/mmr.2014.2753.Cheng X, Wan Y, Xu Y, et al. Melatonin alleviates myosin light chain kinase expression and activity via the mitogen-activated protein kinase pathway during atherosclerosis in rabbits. Mol Med Rep. 2015;11(1):99-104. doi:10.3892/mmr.2014.2753.Ma S, Chen J, Feng J, et al. Melatonin ameliorates the progression of atherosclerosis via Mitophagy activation and NLRP3 Inflammasome inhibition. Oxid Med Cell Longev. 2018;2018:1-12. doi:10.1155/2018/9286458.Ma S, Chen J, Feng J, et al. Melatonin ameliorates the progression of atherosclerosis via Mitophagy activation and NLRP3 Inflammasome inhibition. Oxid Med Cell Longev. 2018;2018:1-12. doi:10.1155/2018/9286458.Hu ZP, Fang XL, Fang N, et al. Melatonin ameliorates vascular endothelial dysfunction, inflammation, and atherosclerosis by suppressing the TLR4/NF-kappaB system in high-fat-fed rabbits. J Pineal Res. 2013;55(4):388-98. doi:10.1111/jpi.12085.47 Hu ZP, Fang XL, Fang N, et al. Melatonin ameliorates vascular endothelial dysfunction, inflammation, and atherosclerosis by suppressing the TLR4/NF-kappaB system in high-fat-fed rabbits. J Pineal Res. 2013;55(4):388-98. doi:10.1111/jpi.12085.Li H, Li J, Jiang X, et al. Melatonin enhances atherosclerotic plaque stability by inducing prolyl-4-hydroxylase alpha 1 expression. J Hypertens. 2019;37(5):964-71. doi: 10.1097/hjh.0000000000001979.Li H, Li J, Jiang X, et al. Melatonin enhances atherosclerotic plaque stability by inducing prolyl-4-hydroxylase alpha 1 expression. J Hypertens. 2019;37(5):964-71. doi: 10.1097/hjh.0000000000001979.Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63(12):1123-33. doi: 10.1016/j.jacc.2013.11.053.Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63(12):1123-33. doi: 10.1016/j.jacc.2013.11.053.Dominguez-Rodriguez A, Abreu-Gonzalez P, Arroyo-Ucar E, et al. Decreased level of melatonin in serum predicts left ventricular remodelling after acute myocardial infarction. J Pineal Res. 2012;53(3):319-23. doi: 10.1111/j.1600-079x.2012.01001.x.Dominguez-Rodriguez A, Abreu-Gonzalez P, Arroyo-Ucar E, et al. Decreased level of melatonin in serum predicts left ventricular remodelling after acute myocardial infarction. J Pineal Res. 2012;53(3):319-23. doi: 10.1111/j.1600-079x.2012.01001.x.Simko F, Bednarova KR, Krajcirovicova K, et al. Melatonin reduces cardiac remodeling and improves survival in rats with isoproterenol-induced heart failure. J Pineal Res. 2014;57(2):177-84. doi:10.1111/jpi.12154.Simko F, Bednarova KR, Krajcirovicova K, et al. Melatonin reduces cardiac remodeling and improves survival in rats with isoproterenol-induced heart failure. J Pineal Res. 2014;57(2):177-84. doi:10.1111/jpi.12154.Odinokova I, Baburina Y, Kruglov A, et al. Effect of melatonin on rat heart mitochondria in acute heart failure in aged rats. Int J Mol Sci. 2018;19(6):1555. doi:10.3390/ijms19061555.Odinokova I, Baburina Y, Kruglov A, et al. Effect of melatonin on rat heart mitochondria in acute heart failure in aged rats. Int J Mol Sci. 2018;19(6):1555. doi:10.3390/ijms19061555.Liu Y, Li LN, Guo S, et al. Melatonin improves cardiac function in a mouse model of heart failure with preserved ejection fraction. Redox Biol. 2018;18:211-21. doi:10.1016/j.redox.2018.07.007.Liu Y, Li LN, Guo S, et al. Melatonin improves cardiac function in a mouse model of heart failure with preserved ejection fraction. Redox Biol. 2018;18:211-21. doi:10.1016/j.redox.2018.07.007.Лискова Ю. В., Саликова С. П., Стадников А. А. Особенности ремоделирования внеклеточного матрикса миокарда левого желудочка крыс с экспериментальной сердечной недостаточностью при введении периндоприла и мелатонина. Кардиология. 2014;54(9):52-6.Liskova Iu V, Salikova SP, Stadnikov AA. Extracellular matrix remodeling myocardium of the left ventricle rats with experimental heart failure after perindopril and melatonin administration. Kardiologiia. 2014;54(9):52-6. (In Russ.)Лискова Ю. В., Саликова С. П., Стадников А. А. Структурная реорганизация миокарда ова-риэктомированных крыс с экспериментальной сердечной недостаточностью при введении мелатонина. Морфология. 2013;144(5):25-9.Liskova IuV, Salikova SP, Stadnikov AA. Structural reorganization of the myocardium in ovariectomized rats with experimental heart failure after melatonin administration. Morfologiia. 2013;144(5):25-9. (In Russ.)

The authors declare that there are no conflicts of interest present.